Table 2.
Results from univariate Kaplan Meier survival analysis showing three-year survival estimates for either the Discovery or TCGA cohorts based on base-line survival estimates along with estimated HRs.
| A Univariate Survival Characteristics Based on 3-year Estimated Overall Survival from Kaplan Meier Estimates in the Discovery Cohort | |||||||
|---|---|---|---|---|---|---|---|
| Discovery Cohort | 3-yr Est Survival | Hazard Ratio | |||||
| Variable | Factor | 3-yr Est Survival |
95% Confidence Interval |
Factor | Hazard Ratio |
95% Confidence Interval |
P-value; Logrank test |
| Race | AA | 0.821 | 0.74–0.91 | AA:nonAA | 1.803 | 0.32–4.44 | 2.00E-01 |
| non-AA | 0.891 | 0.81–0.98 | |||||
| Age at diagnosis | >50 | 0.871 | 0.80–0.95 | >50: ≤50 | 0.630 | 0.27–1.45 | 2.78E-01 |
| ≤50 | 0.820 | 0.72–0.93 | |||||
| Tumor size (cm) | T2+T3 (>=2cm) | 0.833 | 0.74–0.93 | T2+T3: T1 | 1.445 | 0.73–2.83 | 2.84E-01 |
| T1 (<2cm) | 0.917 | 0.84–0.98 | Continuous | 1.300 | 1.11–1.51 | 4.58E-04 | |
| Tumor stage (cm) | I | 0.976 | 0.93–1.00 | II:I | 4.736 | 0.57–39.35 | 1.50E-01 |
| II | 0.913 | 0.84–0.99 | III:I | 21.294 | 2.68–168.69 | 3.78E-03 | |
| III | 0.592 | 0.41–0.86 | |||||
| Involved axilla node(s) | >=1 | 0.762 | 0.65–0.90 | ≥1:0 | 3.342 | 1.51–7.39 | 2.86E-03 |
| 0 | 0.945 | 0.89–1.00 | |||||
| Breast cancer subtypes | TNBC | 0.802 | 0.71–0.91 | TNBC: ER+/PR+/Her2+ | 2.347 | 0.95–5.93 | 6.57E-02 |
| ER+/PR+ or Her2+ | 0.895 | 0.82–0.97 | |||||
| Mesothelin# | mesothelin(+) | 0.772 | 0.66–0.91 | mesothelin(+): mesothelin(−) | 2.031 | 1.10–3.74 | 2.32E-02 |
| mesothelin(−) | 0.893 | 0.83–0.96 | |||||
| B Univariate Analyses to Evaluate Association Between Clinical Covariates and Estimated Overall Survival from Kaplan Meier Estimates in the TCGA Cohort | |||||||
|---|---|---|---|---|---|---|---|
| TCGA Cohort | 3-yr Est Survival | Hazard Ratio | |||||
| Variable | Factor | 3-yr Est Survival |
95% Confidence Interval |
Factor | Hazard Ratio |
95% Confidence Interval |
P-value; Logrank test |
| Race | AA | 0.89 | 0.80–0.99 | AA:nonAA | 0.954 | 0.50–1.81 | 0.89 |
| non-AA | 0.93 | 0.90–0.96 | |||||
| Age at diagnosis | >50 | 0.90 | 0.86–0.94 | >50: ≤50 | 1.302 | 0.80–2.09 | 0.28 |
| ≤50 | 0.94 | 0.91–0.99 | |||||
| Tumor size$ | T1 (<2cm) | 0.94 | 0.89–0.98 | T2:T1 | 1.202 | 0.70–2.07 | 0.51 |
| T2 (2–5cm) | 0.94 | 0.90–0.97 | T3:T1 | 1.013 | 0.48–2.14 | 0.97 | |
| T3 (>5 cm) | 0.87 | 0.78–0.98 | |||||
| Tumor stage (cm) | I | 0.97 | 0.92–1.00 | II:I | 1.301 | 0.68–2.47 | 0.05 |
| II | 0.93 | 0.89–0.97 | III:I | 2.116 | 1.06–4.21 | 0.03 | |
| III | 0.82 | 0.74–0.90 | |||||
| (+) axilla lymph node(s) | ≥1 | 0.89 | 0.85–0.94 | ≥1:0 | 1.604 | 1.18–2.35 | 3.86E-03 |
| 0 | 0.96 | 0.92–0.99 | |||||
| Tumor Receptor Subtypes | TNBC | 0.85 | 0.77–0.95 | TNBC:ER/PR (+) | 2.186 | 1.13–4.22 | 2.85E-03 |
| Her2+ | 0.85 | 0.76–0.96 | Her2 (+):ER/PR (+) | 2.528 | 1.38–4.65 | 0.02 | |
| ER/PR+& Hert2(−) | 0.96 | 0.93–0.98 | |||||
| Mesothelin# | mesothelin(+) | 0.93 | 0.90–0.96 | mesothelin(+): mesothelin(−) | 1.463 | 1.05–2.03 | 0.02 |
| mesothelin(−) | 0.86 | 0.79–0.93 | |||||
AA: African American
#
mesothelin positivity is based on IHC Score dichotimization as described in the methods
AA: African American;
$
Quantiative tumor size (in cm) is not available
#
mesothelin positivity is based on mRNA transcript level-derived dichomization as described in the methods